TransMedics Group, Inc. Income Statement
TMDX / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
TransMedics Group, Inc. reported $605M in revenue and $190M in net income for FY2025. Revenue has grown at a 73.1% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $605.5M | $441.5M | $241.6M | $93.5M | $30.3M | $25.6M | $23.6M | $13.0M |
| Cost of Revenue | $242.7M | $179.5M | $87.5M | $28.2M | $9.1M | $9.0M | $9.7M | $7.3M |
| Gross Profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M | $16.6M | $13.9M | $5.7M |
| SG&A Expense | $185.2M | $168.6M | $119.6M | $69.9M | $38.3M | $24.2M | $23.6M | $12.3M |
| R&D Expense | $69.1M | $56.0M | $36.1M | $26.8M | $22.3M | $18.8M | $19.9M | $13.7M |
| Operating Income | $108.6M | $37.5M | -$28.7M | -$31.4M | -$39.4M | -$26.4M | -$29.6M | -$20.2M |
| Interest Expense | - | - | $10.8M | $3.7M | $3.9M | $4.0M | $4.4M | $2.7M |
| Income Tax | -$82.8M | $316.0K | -$1.6M | $66.0K | - | $0 | $0 | $0 |
| Net Income | $190.3M | $35.5M | -$25.0M | -$36.2M | -$44.2M | -$28.7M | -$9.2M | -$23.8M |
| EPS (Basic) | -$0.77 | -$1.23 | -$1.60 | -$1.16 | -$1.16 | - | - | - |
| EPS (Diluted) | -$0.77 | -$1.23 | -$1.60 | -$1.16 | -$1.16 | -$2.36 | -$8.24 | - |
| Shares Outstanding | 33.6M | 32.7M | 32.1M | 27.8M | 27.2M | 14.2M | 1.3M | 1.3M |
| Gross Margin | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | 64.9% | 58.7% | 44.1% |
| Operating Margin | 17.9% | 8.5% | -11.9% | -33.6% | -130.3% | -102.9% | -125.4% | - |
| Profit Margin | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | -112.1% | -39.0% | -182.5% |